Overview AMX0035 and Progressive Supranuclear Palsy Status: Recruiting Trial end date: 2027-05-31 Target enrollment: Participant gender: Summary ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase. Phase: Phase 3 Details Lead Sponsor: Amylyx Pharmaceuticals Inc.